Capecitabine is an oral chemotherapy drug widely used in the treatment of various cancers, including colorectal and breast cancer. It is a prodrug that converts into 5-fluorouracil (5-FU) in the body, targeting rapidly growing cancer cells while minimizing systemic toxicity. Due to its effectiveness and convenience in oral administration, Capecitabine has become a preferred choice for oncologists worldwide.
India is a leading producer of high-quality generic medicines, including chemotherapy drugs. Several Capecitabine Indian manufacturers are actively engaged in producing cost-effective, high-standard alternatives to branded versions. These manufacturers adhere to international regulatory guidelines such as WHO-GMP, US FDA, and EMA standards, ensuring safety, efficacy, and affordability.
Indian pharmaceutical companies play a crucial role in supplying Capecitabine to both domestic and international markets, making cancer treatment more accessible. With large-scale production capabilities, competitive pricing, and strict quality control measures, Capecitabine Indian manufacturers contribute significantly to global cancer care, ensuring patients receive effective and affordable treatment options.